Newsroom | 1594 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company’s injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commissi...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for o...

LOS ANGELES--(BUSINESS WIRE)--‘Ohh, Mamma!’ AHF’s Free Sexy Burlesque Encore Revisits LA...

WASHINGTON--(BUSINESS WIRE)--AHF Applauds Congress for Backing PEPFAR Funding in Bipartisan Vote...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase IIIb VOLITION study demonstrating that 89% (n=129/145) of eligible treatment-naïve people living with HIV opted to switch to long-acting injectable Vocabria + Rekambys (branded as Cabenuva in the US Canada and Australia) following rapid viral suppression with daily Dovato (dolutegravir/lamivudine (DTG/3TC)). Additional r...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, NCT 07044297) trial will evaluate the safety and efficacy of MK-8527 among people with greater lik...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its use in a long-acting HIV treatment regimen. The announcement follows updated guidance from WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing generic l...

KIGALI, Rwanda--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the largest global AIDS organization, will remind the world that HIV/AIDS is not over by showcasing its innovative, client-centered approaches to the prevention, care and treatment of HIV and other sexually transmitted infections during the 13th International AIDS Society Conference on HIV Science (IAS 2025), taking place in person and virtually July 13–17 in Kigali, Rwanda. AHF will host two dynamic chats at its booth during th...

CIDADE DO MÉXICO--(BUSINESS WIRE)--A AIDS Healthcare Foundation (AHF) denuncia a Gilead Sciences por novamente excluir a América Latina e o Caribe (ALC) do acesso a um medicamento inovador, destinado à prevenção do HIV, denominado lenacapavir. O anúncio de hoje de um acordo de preços e aquisição entre a Gilead e o Fundo Global de Luta contra AIDS, Tuberculose e Malária exclui a maioria dos países da região, obrigando-os a negociar de forma individual e confidencial. "Mais uma vez, a América Lat...

CIUDAD DE MÉXICO--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denuncia a Gilead Sciences por excluir una vez más a América Latina y el Caribe (LAC) del acceso económico a lenacapavir, un revolucionario fármaco para la prevención del VIH. El anuncio de hoy, que comunica un acuerdo de compra y precios entre Gilead y El Fondo Mundial de Lucha contra el Sida, la Tuberculosis y la Malaria, deja afuera a la mayoría de los países de la región y los obliga a negociar unilateralmente y en secreto....